NAMS — NewAmsterdam Pharma NV Cashflow Statement
0.000.00%
Last trade - 00:00- $4.22bn
- $3.48bn
- $45.56m
- 57
- 14
- 98
- 58
Annual cashflow statement for NewAmsterdam Pharma NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | R2021 December 31st | R2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -6.55 | -41.8 | -22.6 | -177 | -242 |
| Depreciation | |||||
| Non-Cash Items | 0.349 | 7.8 | 22.9 | 29.8 | 116 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.602 | 4.47 | 10.4 | 5.87 | -32.7 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -6.8 | -29.5 | 10.7 | -141 | -159 |
| Capital Expenditures | -0.015 | -0.024 | -0.221 | -0.024 | -0.672 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | — | — | — | — | -62.2 |
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.015 | -0.024 | -0.221 | -0.024 | -62.8 |
| Financing Cash Flow Items | — | 0 | -5.79 | 0 | -1.53 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 12.9 | 84.7 | 392 | 8.91 | 660 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 6.11 | 50.5 | 408 | -127 | 431 |